Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies.

Poh W, Dilley RL, Moliterno AR, Maciejewski JP, Pratz KW, McDevitt MA, Herman JG.

Clin Cancer Res. 2019 Apr 15;25(8):2513-2522. doi: 10.1158/1078-0432.CCR-18-0179. Epub 2019 Jan 28.

PMID:
30692098
2.

Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.

Li H, Zhang M, Linghu E, Zhou F, Herman JG, Hu L, Guo M.

Clin Epigenetics. 2018 Nov 6;10(1):137. doi: 10.1186/s13148-018-0570-4.

3.

Facile profiling of molecular heterogeneity by microfluidic digital melt.

O'Keefe CM, Pisanic TR 2nd, Zec H, Overman MJ, Herman JG, Wang TH.

Sci Adv. 2018 Sep 28;4(9):eaat6459. doi: 10.1126/sciadv.aat6459. eCollection 2018 Sep.

4.

Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.

Yan W, Wu K, Herman JG, Xu X, Yang Y, Dai G, Guo M.

Clin Epigenetics. 2018 May 23;10:69. doi: 10.1186/s13148-018-0501-4. eCollection 2018.

5.

Author Correction: Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, de Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):467. doi: 10.1038/s41571-018-0028-9.

PMID:
29713045
6.

Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, De Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):459-466. doi: 10.1038/s41571-018-0004-4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Apr 30;:.

PMID:
29666440
7.

Correction to: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, Zhou F, Song L, Guo M.

Clin Epigenetics. 2018 Mar 14;10:36. doi: 10.1186/s13148-018-0467-2. eCollection 2018.

8.

Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.

Cho JH, Oezkan F, Koenig M, Otterson GA, Herman JG, He K.

Curr Pharmacol Rep. 2017 Dec;3(6):360-373. Epub 2017 Oct 14.

9.

Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.

Volonte D, Vyas AR, Chen C, Dacic S, Stabile LP, Kurland BF, Abberbock SR, Burns TF, Herman JG, Di YP, Galbiati F.

J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.

10.

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.

Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL.

J Cancer. 2017 Oct 23;8(19):3916-3932. doi: 10.7150/jca.20779. eCollection 2017.

11.

Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.

Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, Herman JG, Fuks F, Dong G, Guo M.

Clin Epigenetics. 2017 Oct 23;9:116. doi: 10.1186/s13148-017-0412-9. eCollection 2017.

12.

Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, Zhou F, Song L, Guo M.

Clin Epigenetics. 2017 Oct 18;9:115. doi: 10.1186/s13148-017-0417-4. eCollection 2017. Erratum in: Clin Epigenetics. 2018 Mar 14;10 :36.

13.

Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development.

Wang Y, Zhang Y, Herman JG, Linghu E, Guo M.

Oncotarget. 2017 Jul 25;8(41):70035-70048. doi: 10.18632/oncotarget.19550. eCollection 2017 Sep 19.

14.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

15.

Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.

Gao D, Han Y, Yang Y, Herman JG, Linghu E, Zhan Q, Fuks F, Lu ZJ, Guo M.

Epigenetics. 2017 Jul 3;12(7):575-583. doi: 10.1080/15592294.2017.1341027. Epub 2017 Jul 5.

16.

Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016.

Gao D, Herman JG, Cui H, Jen J, Fuks F, Brock MV, Ushijima T, Croce C, Akiyama Y, Guo M.

Epigenomics. 2017 Jul;9(7):937-941. doi: 10.2217/epi-2017-0030. Epub 2017 May 22.

17.

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).

Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A.

Oncotarget. 2017 Mar 14;8(11):18617. doi: 10.18632/oncotarget.16155. No abstract available.

18.

Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.

He T, Zhang M, Zheng R, Zheng S, Linghu E, Herman JG, Guo M.

Epigenomics. 2017 Jun;9(6):849-862. doi: 10.2217/epi-2017-0019. Epub 2017 Apr 13.

19.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V.

Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15.

20.

GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.

Pelosof L, Yerram S, Armstrong T, Chu N, Danilova L, Yanagisawa B, Hidalgo M, Azad N, Herman JG.

Epigenetics. 2017 Jul 3;12(7):540-550. doi: 10.1080/15592294.2016.1265711. Epub 2016 Dec 5.

21.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

22.

Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling.

Cao B, Yang W, Jin Y, Zhang M, He T, Zhan Q, Herman JG, Zhong G, Guo M.

J Thorac Oncol. 2016 Nov;11(11):1912-1926. doi: 10.1016/j.jtho.2016.06.015. Epub 2016 Jun 30.

23.

Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum.

Hulbert A, Jusue-Torres I, Stark A, Chen C, Rodgers K, Lee B, Griffin C, Yang A, Huang P, Wrangle J, Belinsky SA, Wang TH, Yang SC, Baylin SB, Brock MV, Herman JG.

Clin Cancer Res. 2017 Apr 15;23(8):1998-2005. doi: 10.1158/1078-0432.CCR-16-1371. Epub 2016 Oct 11.

24.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

25.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

26.

WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.

Bosch LJ, Luo Y, Lao VV, Snaebjornsson P, Trooskens G, Vlassenbroeck I, Mongera S, Tang W, Welcsh P, Herman JG, Koopman M, Nagtegaal ID, Punt CJ, van Criekinge W, Meijer GA, Monnat RJ Jr, Carvalho B, Grady WM.

Clin Cancer Res. 2016 Sep 15;22(18):4612-22. doi: 10.1158/1078-0432.CCR-15-2703. Epub 2016 Apr 27.

27.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH.

Clin Cancer Res. 2016 Aug 1;22(15):3894-902. doi: 10.1158/1078-0432.CCR-15-2351. Epub 2016 Mar 15.

28.

The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.

Gao D, Herman JG, Guo M.

Oncotarget. 2016 Jun 14;7(24):37331-37346. doi: 10.18632/oncotarget.7949. Review.

29.

On Predicting lung cancer subtypes using 'omic' data from tumor and tumor-adjacent histologically-normal tissue.

Pineda AL, Ogoe HA, Balasubramanian JB, Rangel Escareño C, Visweswaran S, Herman JG, Gopalakrishnan V.

BMC Cancer. 2016 Mar 4;16:184. doi: 10.1186/s12885-016-2223-3.

30.

Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling.

Zhang M, Linghu E, Zhan Q, He T, Cao B, Brock MV, Herman JG, Xiang R, Guo M.

Oncotarget. 2016 Apr 5;7(14):17957-69. doi: 10.18632/oncotarget.7647.

31.

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).

Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A.

Oncotarget. 2016 May 3;7(18):24950-61. doi: 10.18632/oncotarget.7436. Erratum in: Oncotarget. 2017 Mar 14;8(11):18617.

32.

Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.

Dong T, Zhang M, Dong Y, Herman JG, van Engeland M, Zhong G, Guo M.

Discov Med. 2015 Nov;20(111):261-71.

33.

Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer.

Jia Y, Cao B, Yang Y, Linghu E, Zhan Q, Lu Y, Yu Y, Herman JG, Guo M.

Oncotarget. 2015 Oct 20;6(32):33470-85. doi: 10.18632/oncotarget.5272.

34.

Epigenome-based personalized medicine in human cancer.

Yan W, Herman JG, Guo M.

Epigenomics. 2016 Jan;8(1):119-33. doi: 10.2217/epi.15.84. Epub 2015 Sep 7. Review.

35.

DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.

Pisanic TR 2nd, Athamanolap P, Poh W, Chen C, Hulbert A, Brock MV, Herman JG, Wang TH.

Nucleic Acids Res. 2015 Dec 15;43(22):e154. doi: 10.1093/nar/gkv795. Epub 2015 Aug 24.

36.
37.

Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth.

Dong Y, Cao B, Zhang M, Han W, Herman JG, Fuks F, Zhao Y, Guo M.

Oncotarget. 2015 Sep 8;6(26):22126-38.

38.

Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer.

Calmon MF, Jeschke J, Zhang W, Dhir M, Siebenkäs C, Herrera A, Tsai HC, O'Hagan HM, Pappou EP, Hooker CM, Fu T, Schuebel KE, Gabrielson E, Rahal P, Herman JG, Baylin SB, Ahuja N.

Epigenetics. 2015;10(7):622-32. doi: 10.1080/15592294.2015.1050173.

39.

Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling.

Hu S, Cao B, Zhang M, Linghu E, Zhan Q, Brock MV, Herman JG, Mao G, Guo M.

Am J Cancer Res. 2015 Jan 15;5(2):651-62. eCollection 2015.

40.

Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.

Li X, Yu J, Brock MV, Tao Q, Herman JG, Liang P, Guo M.

Oncotarget. 2015 May 10;6(13):11547-60.

41.

Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.

Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M.

Clin Cancer Res. 2015 Aug 1;21(15):3492-500. doi: 10.1158/1078-0432.CCR-14-2049. Epub 2015 Apr 22.

42.

CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.

Guo M, Alumkal J, Drachova T, Gao D, Marina SS, Jen J, Herman JG.

Discov Med. 2015 Mar;19(104):151-8.

43.

Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.

Yun T, Liu Y, Gao D, Linghu E, Brock MV, Yin D, Zhan Q, Herman JG, Guo M.

Genes Cancer. 2015 Jan;6(1-2):38-48.

44.

RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.

Guo J, Yang Y, Yang Y, Linghu E, Zhan Q, Brock MV, Herman JG, Zhang B, Guo M.

Oncotarget. 2015 Feb 28;6(6):4202-13.

45.

Epigenetic changes and functional study of HOXA11 in human gastric cancer.

Cui Y, Gao D, Linghu E, Zhan Q, Chen R, Brock MV, Herman JG, Guo M.

Epigenomics. 2015;7(2):201-13. doi: 10.2217/epi.14.92. Epub 2015 Jan 15.

PMID:
25590359
46.

Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood.

Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, Wouters KA, Louwagie J, Schuebel KE, Herman JG, Baylin SB, van Criekinge W, Meijer GA, Ahuja N, van Engeland M.

Cancer Prev Res (Phila). 2015 Feb;8(2):157-64. doi: 10.1158/1940-6207.CAPR-14-0198. Epub 2014 Dec 23.

47.

DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling.

Yu Y, Yan W, Liu X, Jia Y, Cao B, Yu Y, Lv Y, Brock MV, Herman JG, Licchesi J, Yang Y, Guo M.

Am J Cancer Res. 2014 Nov 19;4(6):710-24. eCollection 2014.

48.

Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.

Zhao Z, Herman JG, Brock MV, Sheng J, Zhang M, Liu B, Guo M.

PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014.

49.

DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers.

Ovchinnikov DA, Wan Y, Coman WB, Pandit P, Cooper-White JJ, Herman JG, Punyadeera C.

Biomark Insights. 2014 Jul 3;9:53-60. doi: 10.4137/BMI.S16199. eCollection 2014.

50.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

Supplemental Content

Loading ...
Support Center